New launch Atrium will focus on RNA medicines for cardiomyopathy
Atrium Therapeutics has launched as a newly independent, publicly traded company developing RNA therapeutics for people living with rare, life-threatening genetic cardiomyopathies. Atrium Therapeutics was established in connection with Avidity Biosciences’ acquisition by Novartis. The company is led by Kathleen Gallagher, President and Chief Executive Officer (CEO),… Read More